IL135887A0 - Unducible phosphofructokinase and the warburg effect - Google Patents

Unducible phosphofructokinase and the warburg effect

Info

Publication number
IL135887A0
IL135887A0 IL13588798A IL13588798A IL135887A0 IL 135887 A0 IL135887 A0 IL 135887A0 IL 13588798 A IL13588798 A IL 13588798A IL 13588798 A IL13588798 A IL 13588798A IL 135887 A0 IL135887 A0 IL 135887A0
Authority
IL
Israel
Prior art keywords
ipfk
unducible
phosphofructokinase
warburg effect
cancer
Prior art date
Application number
IL13588798A
Other languages
English (en)
Original Assignee
Picower Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Inst Med Res filed Critical Picower Inst Med Res
Publication of IL135887A0 publication Critical patent/IL135887A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/011056-Phosphofructo-2-kinase (2.7.1.105)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
IL13588798A 1997-10-31 1998-10-30 Unducible phosphofructokinase and the warburg effect IL135887A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/961,578 US6413939B1 (en) 1997-10-31 1997-10-31 Inducible phosphofructokinase and the Warburg effect
PCT/US1998/023155 WO1999023108A1 (en) 1997-10-31 1998-10-30 Inducible phosphofructokinase and the warburg effect

Publications (1)

Publication Number Publication Date
IL135887A0 true IL135887A0 (en) 2001-05-20

Family

ID=25504669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13588798A IL135887A0 (en) 1997-10-31 1998-10-30 Unducible phosphofructokinase and the warburg effect

Country Status (10)

Country Link
US (4) US6413939B1 (xx)
EP (1) EP1042350B1 (xx)
JP (1) JP4369044B2 (xx)
AT (1) ATE417054T1 (xx)
AU (1) AU1370799A (xx)
CA (1) CA2308091A1 (xx)
DE (1) DE69840342D1 (xx)
ES (1) ES2319345T3 (xx)
IL (1) IL135887A0 (xx)
WO (1) WO1999023108A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0216097D0 (en) * 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP1656376A1 (en) * 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20060166236A1 (en) * 2004-12-15 2006-07-27 Chong-Sheng Yuan Allosteric enzyme coupled immunoassay (AECIA)
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8662667B2 (en) * 2007-12-21 2014-03-04 Carl Zeiss Meditec Ag Ophthalmologic visualization system
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
WO2012040108A2 (en) * 2010-09-20 2012-03-29 Caliper Life Sciences Multivalent fluorescent probes
EP2532747B1 (en) * 2011-06-09 2015-12-02 Deutsches Krebsforschungszentrum Modulators of glycerol-3-phosphate dehydrogenase (GPD2) for therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015674A1 (en) * 1995-10-24 1997-05-01 Garvan Institute Of Medical Research Progestin-regulated gene
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect

Also Published As

Publication number Publication date
US6255046B1 (en) 2001-07-03
DE69840342D1 (de) 2009-01-22
US20030228568A1 (en) 2003-12-11
EP1042350A4 (en) 2003-01-02
US6413939B1 (en) 2002-07-02
WO1999023108A9 (en) 1999-08-19
ES2319345T3 (es) 2009-05-06
WO1999023108A1 (en) 1999-05-14
JP4369044B2 (ja) 2009-11-18
EP1042350B1 (en) 2008-12-10
AU1370799A (en) 1999-05-24
JP2001521731A (ja) 2001-11-13
EP1042350A1 (en) 2000-10-11
ATE417054T1 (de) 2008-12-15
US6596851B1 (en) 2003-07-22
CA2308091A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
IL135887A0 (en) Unducible phosphofructokinase and the warburg effect
Zwelling et al. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis-and trans-diamminedichloroplatinum (II)
Millard et al. Determination of the DNA crosslinking sequence specificity of reductively activated mitomycin C at single-nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially
BG100293A (en) 2,8-disubstituted quinazolinons
PT876387E (pt) Utilizacao de roxitromicina para a preparacao de um medicamento para melhorar a actividade biologica e antiviral de inibidores da protease
GB9411671D0 (en) Tumor diagnosis and prognosis
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
EP2116262A3 (en) Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
MX9304501A (es) Quimioterapia para cancer.
CA2362917A1 (en) Methods for anti-tumor therapy
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO2001085219A3 (en) Identification, diagnosis, and treatment of breast cancer
WO2002024947A3 (en) Cancer associated protein kinases and their uses
Wick Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells
HK1002531A1 (en) New tumor diagnosing or therapeutical probe
NZ509215A (en) Transdermal plaster preparation containing at least one active ingredient which influences blood serum lipid levels
ATE200427T1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
Li et al. Plant sterols as selective DNA polymerase β lyase inhibitors and potentiators of bleomycin cytotoxicity
HUP0300007A2 (en) Antibody with specificity for colon cancer
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
Rykova et al. Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood
Baguley et al. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine
Ho et al. Pharmacological studies of the antitumor agent 6-methylthiopurine ribonucleoside
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy